IBL-302

Project "IBL-302" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Breast cancer is already a leading cause of death among women and most common form of cancer among European women with almost 500,000 cases in 2012 and over 1.7 million new cases globally. However, despite good progress in treatment options over the past decade, including some progress with immunotherapies, the war is far from won, with over 20% not responding to current standard care, and with the incidence of breast cancer set to rise by a massive 50% by 2030. There is now an urgent need for new effective, safe and life extending therapeutics for those women suffering and dying with breast cancer. IBL-302 is a first-in-class small molecule targeted breast cancer therapeutic that targets both the PI3K and PIM pathways. It is an orally bioavailable pan-PIM kinase, pan-PI3K and mTOR inhibition in a single agent. As the PI3K pathway is one of the most commonly mutated pathways, this multi-path action effect closes down the main route of mutation and a primary backup PIM pathway. This confers the promise of much greater rates of efficacy and potential utility to combat the breast cancer epidemic. Inhibition of the PI3K pathway alone is cytostatic, it pauses cell growth but does not kill cancer cells. This has the effect of the PIM pathways then being activated as a backup mutation pathway, allowing the cancer to progress once more. Adding PIM inhibition on top of the PI3K inhibition actually induces apoptosis, the death of cancer cells instead of simply stalling their growth. A development partnership will be sought with a large pharmaceutical company to complete final stages of clinical development required for market approval. The partner will also be responsible for the manufacture and distribution IBL-302 on an exclusive licence.